Keystone Resort Floorplan
Registered Attendees
Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:
- Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting
(You can edit your own abstract from My Account page as well)
NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.
- Full participant list, including joint meeting participants
- Printable Invoices and Invitation Letters
- Scholarship Information
- Lodging Information
Login to My Account page
This meeting took place in 2014
Here are the related meetings in 2018:
Frontiers in Islet Biology and Diabetes (B3)
For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.
Emerging Concepts and Targets in Islet Biology (D3)
Organizer(s) Rohit N. Kulkarni, Raghavendra G. Mirmira and Eckhard Lammert
April 6—11, 2014
Keystone Resort • Keystone, Colorado USA
Discounted Abstract Deadline: Dec 9, 2013
Abstract Deadline: Jan 14, 2014
Scholarship Deadline: Dec 9, 2013
Discounted Registration Deadline: Feb 5, 2014
Sponsored by Sanofi US.
Summary of Meeting:
This meeting focuses on signaling pathways that impact islet cell physiology via their ability to enhance the function, promote survival and/or increase proliferation of islet cells. This is a crucial area of islet biology that has not been the focus of recent scientific meetings and is therefore timely with respect to new therapeutic approaches to combat diabetes. The meeting includes a discussion of potential drug targets involving islet cells, both localized to the islet milieu and from different organ systems, as well as of genes newly discovered to be involved in islet dysfunction. In addition, since efforts aimed at assessing the efficacy of drug targeting require means to quantitatively assess islet responses in vivo, the meeting includes a session focused on non-invasive assessment of beta cell mass and function. Finally, workshops cover areas of major interest to the scientific community (academia and industry): drug targets currently in clinical trials; stem cell and iPS research investments; and the procurement and distribution of high-quality human islets and pancreas samples for research work.
View Scholarships/Awards
This meeting focuses on signaling pathways that impact islet cell physiology via their ability to enhance the function, promote survival and/or increase proliferation of islet cells. This is a crucial area of islet biology that has not been the focus of recent scientific meetings and is therefore timely with respect to new therapeutic approaches to combat diabetes. The meeting includes a discussion of potential drug targets involving islet cells, both localized to the islet milieu and from different organ systems, as well as of genes newly discovered to be involved in islet dysfunction. In addition, since efforts aimed at assessing the efficacy of drug targeting require means to quantitatively assess islet responses in vivo, the meeting includes a session focused on non-invasive assessment of beta cell mass and function. Finally, workshops cover areas of major interest to the scientific community (academia and industry): drug targets currently in clinical trials; stem cell and iPS research investments; and the procurement and distribution of high-quality human islets and pancreas samples for research work.
View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference
SUNDAY, APRIL 6
MONDAY, APRIL 7
TUESDAY, APRIL 8
WEDNESDAY, APRIL 9
THURSDAY, APRIL 10
FRIDAY, APRIL 11
Conference Program Print | View meeting in 12 hr (am/pm) time
SUNDAY, APRIL 6
08:00—08:05
Opening Remarks
Meeting has ended...abstracts no longer viewable online.
Rohit N. Kulkarni,
Joslin Diabetes Center, Harvard Medical School, USA
Raghavendra G. Mirmira,
Indiana University School of Medicine, USA
Eckhard Lammert,
Heinrich-Heine-University / German Diabetes Center, Germany
08:05—09:00
Keynote Address
Meeting has ended...abstracts no longer viewable online.
*
Rohit N. Kulkarni,
Joslin Diabetes Center, Harvard Medical School, USA
C. Ronald Kahn,
Joslin Diabetes Center and Harvard Medical School, USA
Novel Signaling Pathways Relevant for Targeting Metabolism
Novel Signaling Pathways Relevant for Targeting Metabolism
09:00—11:15
New Insights into Beta Cells Signaling Pathways
Meeting has ended...abstracts no longer viewable online.
*
Raghavendra G. Mirmira,
Indiana University School of Medicine, USA
Adolfo Garcia-Ocaña,
Ichan School of Medicine at Mount Sinai, USA
PKC-Zeta Signaling in the Beta Cell
PKC-Zeta Signaling in the Beta Cell
Carmella Evans-Molina,
Indiana University, USA
Regulation of ER Calcium Homeostasis in the Diabetic beta Cell
Regulation of ER Calcium Homeostasis in the Diabetic beta Cell
Rohit N. Kulkarni,
Joslin Diabetes Center, Harvard Medical School, USA
New Concepts in Growth Factor Signaling in Islet Cells
New Concepts in Growth Factor Signaling in Islet Cells
Justin P. Annes,
Stanford University, USA
Short Talk: Repurposing cAMP-Modulating Medications to Promote beta-Cell Replication
Short Talk: Repurposing cAMP-Modulating Medications to Promote beta-Cell Replication
14:30—16:30
Workshop 1: Drug Targets in Clinical Trials
*
Sonya G. Fonseca,
Novartis, USA
*
Anke Schulte,
Sanofi-Aventis, Germany
Krister B. Bokvist,
Sanofi-Aventis Deutschland GmbH, Germany
A Fixed Duration Combination Treatment with Gastrin and GLP-1 Analogues does not Result in Lasting Post-Treatment Improvements in Glycaemic Control in Type 2 Diabetes Patients
A Fixed Duration Combination Treatment with Gastrin and GLP-1 Analogues does not Result in Lasting Post-Treatment Improvements in Glycaemic Control in Type 2 Diabetes Patients
Freimut Schliess,
Profil GmbH, Germany
The NMDA Receptor Antagonist Dextromethorphan Reduces OGTT-Related Glycaemia in Patients with T2DM: A Randomized, Double Blind, Placebo-Controlled, Fourfold Cross-Over Clinical Trial
The NMDA Receptor Antagonist Dextromethorphan Reduces OGTT-Related Glycaemia in Patients with T2DM: A Randomized, Double Blind, Placebo-Controlled, Fourfold Cross-Over Clinical Trial
Rowena Suriben,
Genentech Inc., USA
Short Talk: Misregulated ETV Protein Levels in Cop1 Mutant beta-Cells Results in Defective Insulin Secretion and Diabetes
Short Talk: Misregulated ETV Protein Levels in Cop1 Mutant beta-Cells Results in Defective Insulin Secretion and Diabetes
17:00—19:00
The Role of Non-Beta Cells in Glucose Homeostasis
Meeting has ended...abstracts no longer viewable online.
*
Patrick MacDonald,
University of Alberta, Canada
Patrik Rorsman,
Oxford Centre for Diabetes, Endocrinology and Metabolism, UK
Signaling in the Regulation of alpha-Cells: Role of Calcium and Ion Channels
Signaling in the Regulation of alpha-Cells: Role of Calcium and Ion Channels
Patricia M. Vuguin,
Cohen Children's Hospital, North Shore / LIJ, Hofstra University, USA
Lack of Glucagon Receptor Signaling and its Implications beyond Glucose Homeostasis
Lack of Glucagon Receptor Signaling and its Implications beyond Glucose Homeostasis
Jeffrey M. Zigman,
University of Texas Southwestern Medical Center, USA
Ghrelin Signaling in Modulation of Alpha Cells
Ghrelin Signaling in Modulation of Alpha Cells
Sofie S. Nielsen,
University of Copenhagen, Denmark
Short Talk: The Effect of Bone Morphogenetic Protein 4 (BMP4) on Pancreatic Alpha Cell Function
Short Talk: The Effect of Bone Morphogenetic Protein 4 (BMP4) on Pancreatic Alpha Cell Function
08:00—11:00
Novel Drug Targets to Enhance Beta Cell Function
Meeting has ended...abstracts no longer viewable online.
*
Maureen Gannon,
Vanderbilt University, USA
Eckhard Lammert,
Heinrich-Heine-University / German Diabetes Center, Germany
Targeting NMDA Receptors in Pancreatic Islets: A Novel Adjunct Treatment for Type 2 Diabetes
Targeting NMDA Receptors in Pancreatic Islets: A Novel Adjunct Treatment for Type 2 Diabetes
Vijay K. Yechoor,
University of Pittsburgh, USA
Talk Title to be Announced
Talk Title to be Announced
Mehboob Hussain,
Johns Hopkins University School of Medicine, USA
A Liver-Derived Endocrine Inhibitor of Beta-Cell Function
A Liver-Derived Endocrine Inhibitor of Beta-Cell Function
Heiko Lickert,
Institute of Diabetes and Regeneration, Germany
Short Talk: Targeting beta-Cell Heterogeneity in the Islet of Langerhans
Short Talk: Targeting beta-Cell Heterogeneity in the Islet of Langerhans
14:30—16:30
Workshop 2: Update on Investments in Stem Cell and iPS Research
*
Melissa K. Thomas,
Lilly Research Laboratories, USA
Mark C. Zimmerman,
Janssen Research & Development, USA
Overview of the Use of ES and iPS Cells for Therapeutics
Overview of the Use of ES and iPS Cells for Therapeutics
Jennifer E. Bruin,
University of British Columbia, Canada
Treating Diabetes with Islets Derived from Human Embryonic Stem Cells
Treating Diabetes with Islets Derived from Human Embryonic Stem Cells
Adrianne Wong,
Juvenile Diabetes Research Foundation, USA
Investments/Interests on iPS/ES Cells for Therapy
Investments/Interests on iPS/ES Cells for Therapy
Brian Lu,
Mayo Clinic, USA
Short Talk: Beta-Cell Targeted Gene Delivery for Enhanced beta-Cell Proliferation
Short Talk: Beta-Cell Targeted Gene Delivery for Enhanced beta-Cell Proliferation
17:00—19:00
Novel Drug Targets to Preserve and/or Promote Proliferation of Beta Cells
Meeting has ended...abstracts no longer viewable online.
*
Nils Billestrup,
University of Copenhagen, Denmark
Raghavendra G. Mirmira,
Indiana University School of Medicine, USA
The Role of Deoxyhypusine Synthase and mRNA Translation during beta Cell Stress
The Role of Deoxyhypusine Synthase and mRNA Translation during beta Cell Stress
Maureen Gannon,
Vanderbilt University, USA
Connective Tissue Growth Factor-Mediated Beta-Cell Proliferation and Regeneration
Connective Tissue Growth Factor-Mediated Beta-Cell Proliferation and Regeneration
Fumihiko Urano,
Washington University School of Medicine, USA
Targeting Endoplasmic Reticulum for Combating Wolfram Syndrome and Type 1 Diabetes
Targeting Endoplasmic Reticulum for Combating Wolfram Syndrome and Type 1 Diabetes
Karim Bouzakri,
Geneva University, Switzerland
Short Talk: Protective Effects of Fractalkine (CX3CL1) on beta-Cells
Short Talk: Protective Effects of Fractalkine (CX3CL1) on beta-Cells
08:00—11:00
Targeting Extra-Pancreatic Tissues to Regulate Beta Cell Biology - Systemic Communication
Meeting has ended...abstracts no longer viewable online.
*
Rohit N. Kulkarni,
Joslin Diabetes Center, Harvard Medical School, USA
Gerard Karsenty,
Columbia University Medical Center, USA
Insulin Resistance in Bone: Molecular Bases and Metabolic Consequences
Insulin Resistance in Bone: Molecular Bases and Metabolic Consequences
Josephine Egan,
NIA, National Institutes of Health, USA
Significance of Targeting Cannabinoids in the Periphery to Regulate Beta-Cell Function and Survival
Significance of Targeting Cannabinoids in the Periphery to Regulate Beta-Cell Function and Survival
Peng Yi,
Joslin Diabetes Center, USA
Betatrophin
Betatrophin
Rupangi C. Vasavada,
Icahn School of Medicine at Mount Sinai, USA
A Novel Circulating Bone-Related Factor in the Regulation of Beta-Cells
A Novel Circulating Bone-Related Factor in the Regulation of Beta-Cells
Abdelfattah El Ouaamari,
Joslin Diabetes Center, USA
Short Talk: Identification of a Novel beta-Cell Growth Factor Derived from the Liver
Short Talk: Identification of a Novel beta-Cell Growth Factor Derived from the Liver
17:00—19:00
Targeting Local Innervation and Vascularization to Regulate Beta Cell Biology - Intra-Islet Communication
Meeting has ended...abstracts no longer viewable online.
*
Eckhard Lammert,
Heinrich-Heine-University / German Diabetes Center, Germany
Alejandro Caicedo,
University of Miami, USA
Human Pancreatic Islets Are Less Nervous and More Self-Sufficient
Human Pancreatic Islets Are Less Nervous and More Self-Sufficient
Per-Ola Carlsson,
Uppsala University, Sweden
Influence of Vascularization on Beta Cell Function and Mass
Influence of Vascularization on Beta Cell Function and Mass
Marcela Brissova,
Vanderbilt University, USA
Targeting Islet Vascularization to Regulate Beta Cell Biology
Targeting Islet Vascularization to Regulate Beta Cell Biology
Richard KP Benninger,
University of Colorado, USA
Short Talk: A Critical Balance between KATP Activity and Gap Junction Coupling Determines Islet Dysfunction and Diabetes
Short Talk: A Critical Balance between KATP Activity and Gap Junction Coupling Determines Islet Dysfunction and Diabetes
08:00—11:00
Non-Invasive Assessment of Beta Cell Function and Mass
Meeting has ended...abstracts no longer viewable online.
*
Stephan Speier,
Technische Universität Dresden, Germany
Olof Eriksson,
Uppsala University, Sweden
The Glucagon Like Peptide-1 Receptor as an Imaging Biomarker of Beta Cell Mass
The Glucagon Like Peptide-1 Receptor as an Imaging Biomarker of Beta Cell Mass
Markus Stoffel,
ETH Zürich, Switzerland
MicroRNAs in Beta Cells: Function and Diagnostic and Therapeutic Implications
MicroRNAs in Beta Cells: Function and Diagnostic and Therapeutic Implications
Eckhard Wolf,
Ludwig-Maximilians-Universität (LMU) Munich, Germany
The GIPRdn Pig as a Model to Identify Biomarkers of Subclinical Diabetes
The GIPRdn Pig as a Model to Identify Biomarkers of Subclinical Diabetes
Kevan C. Herold,
Yale University, USA
Insulin Gene Methylation as a Marker of Beta Cell Death
Insulin Gene Methylation as a Marker of Beta Cell Death
Chunguang Chen,
Technische Universität Dresden, Germany
Short Talk: In vivo Kinetics of Islet Compensation and Dysfunction in a Mouse Model of Diet-Induced Obesity and Insulin Resistance
Short Talk: In vivo Kinetics of Islet Compensation and Dysfunction in a Mouse Model of Diet-Induced Obesity and Insulin Resistance
14:30—16:30
Workshop 3: Human Islet Procurement and Distribution
Barbara Olack,
City of Hope, USA
Perspectives from the Distributor: Logistics and Obstacles to Human Islet Isolation and Distribution
Perspectives from the Distributor: Logistics and Obstacles to Human Islet Isolation and Distribution
*
Andrew F. Stewart,
Mount Sinai School of Medicine, USA
Perspective from the User on Availability of High Quality Human Islets for Research
Perspective from the User on Availability of High Quality Human Islets for Research
Andrew Rakeman,
Juvenile Diabetes Research Foundation, USA
On the Importance of Studying Human Disease: Pancreas from Patients with T1D and the JDRF-nPOD Program
On the Importance of Studying Human Disease: Pancreas from Patients with T1D and the JDRF-nPOD Program
Julie Donaldson,
ALPCO, USA
Short Talk: Development of Novel Broad Range, Highly Sensitive, Small Volume Chemiluminescent Assays for Beta-Cell Profiling
Short Talk: Development of Novel Broad Range, Highly Sensitive, Small Volume Chemiluminescent Assays for Beta-Cell Profiling
17:00—19:00
Novel Genes Involved in Islet Dysfunction
Meeting has ended...abstracts no longer viewable online.
*
Markus Stoffel,
ETH Zürich, Switzerland
Michael German,
University of California, San Francisco, USA
Transcriptional Cascade Controlling Beta-Cell Differentiation
Transcriptional Cascade Controlling Beta-Cell Differentiation
Charlotte A. Ling,
Lund University, Sweden
TFBM1 and its Variants as Regulators of Islet Function and Development of Diabetes
TFBM1 and its Variants as Regulators of Islet Function and Development of Diabetes
Franck Mauvais-Jarvis,
Tulane University Health Sciences Center, USA
Short Talk: Novel Actions of the Androgen Receptor in Glucose-Stimulated Insulin Secretion in Males
Short Talk: Novel Actions of the Androgen Receptor in Glucose-Stimulated Insulin Secretion in Males
19:00—19:05
Closing Remarks
Meeting has ended...abstracts no longer viewable online.
Rohit N. Kulkarni,
Joslin Diabetes Center, Harvard Medical School, USA
Raghavendra G. Mirmira,
Indiana University School of Medicine, USA
Eckhard Lammert,
Heinrich-Heine-University / German Diabetes Center, Germany
*Session Chair †Invited, not yet responded.
We gratefully acknowledge support for this conference from:
Keystone Symposia thanks our Sponsor for generously supporting this meeting:
|
|
We gratefully acknowledge the generous grant for this conference provided by:
We gratefully acknowledge additional support for this conference from:
|
|
We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:
Click here to view more of these organizations
Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:
Click here to view more of these organizations
|
If your organization is interested in joining these entities in support of Keystone
Symposia, please contact: Sarah Lavicka,
Director of Development, Email: sarahl@keystonesymposia.org, Phone:+1 970-262-2690 Click here for more information on Industry Support and Recognition Opportunities. If you are interested in becoming an advertising/marketing in-kind partner, please contact: Yvonne Psaila, Director, Marketing and Communications, Email: yvonnep@keystonesymposia.org, Phone:+1 970-262-2676 |
